Response rates in a key group shrink from 62% to 39% as the company blames a “clerical error”.
ApexOnco Front Page
Recent articles
What similarly acting projects are still unpartnered?
How does the micro-cap biotech now finance a 700-patient phase 3 study?
A mysterious ASCO poster, patient deaths and now clinical hold; where next for BioNTech’s ADC deal?
The company’s SGR-3515 features among the latest industry projects newly into first-in-human trials.
NX-5948 and BGB-16673 yield data in more CLL patients, but Nurix investors seem unimpressed.
Imfinzi scores an unexpected approval based on a post-hoc subgroup analysis.
More details on cardiovascular events with the group’s anti-CD47 project comforted analysts, but shares still fell 10%.
